Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

Preclinical and early clinical studies suggest that combining epigenetic agents with checkpoint inhibitors can potentially improve outcomes in patients with previously treated advanced non-small cell lung cancer (NSCLC). This phase 2 trial examined second-line pembrolizumab  + CC-486 (oral azacitidine) in patients with advanced NSCLC.

Source: European Journal of Cancer - January 14, 2019 Category: Cancer & Oncology Authors: Benjamin P. Levy, Giuseppe Giaccone, Benjamin Besse, Enriqueta Felip, Marina Chiara Garassino, Manuel Domine Gomez, Pilar Garrido, Bilal Piperdi, Santiago Ponce-Aix, Daniel Menezes, Kyle J. MacBeth, Alberto Risue ño, Ruta Slepetis, Xiaoling Wu, Abderrahi Tags: Original Research Source Type: research